Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Drugs in Dermatology : JDD|October 2, 2025
Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic DermatitisLeon Kircik, Daniel Sturm, Howard Kallender, et al.
Investigational New Drugs|August 25, 2012
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neckTanguy Seiwert, John Sarantopoulos, Howard Kallender, et al.
Dermatology and Therapy|October 7, 2024
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication HistoryAndrew Blauvelt, Howard Kallender, Daniel Sturm, et al.
The Journal of Biological Chemistry|August 5, 2004
Staphylococcus aureus 3-hydroxy-3-methylglutaryl-CoA synthase: crystal structure and mechanismNino Campobasso, Mehul Patel, Imogen E Wilding, et al.
Journal of Clinical Pharmacology|May 23, 2015
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumorsRajendra P Singh, Bela Patel, Howard Kallender, et al.
Dermatology and Therapy|July 12, 2024
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 StudiesEric L Simpson, Leon Kircik, Andrew Blauvelt, et al.
Tuberculosis (Edinburgh, Scotland)|November 5, 2004
Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesisM L Merrill L Schaeffer, J D Jeffrey D Carson, Howard Kallender, et al.
The Journal of Dermatology|October 13, 2023
Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapyEric L Simpson, Leon Kircik, Andrew Blauvelt, et al.
The Journal of Dermatological Treatment|February 1, 2024
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studiesEric L Simpson, Robert Bissonnette, Zelma C Chiesa Fuxench, et al.
American Journal of Clinical Dermatology|January 6, 2025
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic DermatitisLinda Stein Gold, Robert Bissonnette, Seth Forman, et al.
Pageof 3